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Behc¸et’s disease (BD) is a multisystemic disorder of unknown etiology mainly defined by recurrent oral aphthosis, genital ulcers,
and chronic relapsing bilateral uveitis, all of which represent the “stigmata” of disease. However, many other organs including the
vascular, neurological, musculoskeletal, and gastrointestinal systems can be affected. The gastrointestinal involvement in Behc¸et’s
disease (GIBD), along with the neurological and vascular ones, represents the most feared clinical manifestation of BD and shares
many symptoms with inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. Consequently, the differential
diagnosis is often a daunting task, albeit the presence of typical endoscopic and pathologic findings may be a valuable aid to the
exact diagnosis. To date, there are no standardized medical treatments for GIBD; therefore therapy should be tailored to the single
patient and based on the severity of the clinical features and their complications.Thiswork provides a digest of all current experience
and evidence about pharmacological agents suggested by themedical literature as having a potential role for managing the dreadful
features of GIBD.
1. Introduction
Behc¸et’s disease (BD) is a rare relapsing systemic inflamma-
tory disorder of unknown etiology characterized by recurrent
oral ulcers, genital sores, and ocular lesions; however many
other organs including the vascular, neurological, and mus-
culoskeletal systems as well as the gastrointestinal system can
be involved [1–3]. Genetic and environmental factors play a
key role in this disorder, in particular the human leukocyte
antigen B51 allele, located in the major histocompatibility
complex locus, representing the strongest risk factor for the
development of BD [4]. In recent years, some microbial
agents such as Herpes simplex virus 1 and Streptococcus san-
guinis have gained increasing importance as potential infec-
tious agents of BD [5], being able to generate an inflammatory
process leading to a CD4+ T lymphocytes clonal expansion
which in turn produces high concentrations of both proin-
flammatory cytokines and cytotoxic CD8+ cells [6]. Several
cytokines are claimed to contribute to the pathological
scenario of BD [5, 7–9]: tumor necrosis factor- (TNF-) 𝛼
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Table 1: Main clinical, endoscopic, and pathological features of gastrointestinal involvement in Behc¸et’s disease and most common
localization.
Behc¸et’s disease Crohn’s disease Ulcerative colitis
Gastrointestinal
manifestations
Anorexia, vomiting,
dyspepsia, diarrhoea,
abdominal pain, melena,
hematochezia, fever
Anorexia, vomiting,
dyspepsia, diarrhea,
gastrointestinal
bleeding, abdominal
pain, fever
Rectal bleeding,
diarrhoea, tenesmus,
abdominal pain,
hematochezia, fever
Pathological
features
Vasculitis of the
small veins and venules
with deep ulcerations,
generally
without granulomas or
cobblestoning,
ischemic perforation,
thrombosis
Transmural mucosal
inflammation,
inflammatory cell
infiltrate (lymphocytes,
plasma cells) with focal
crypt irregularity and
independent granulomas
Distortion of crypt
architecture,
crypt abscesses, lamina
propria cellular
infiltration (plasma cells,
eosinophils,
lymphocytes),
shortening of the crypts,
mucin depletion,
lymphoid aggregates,
erosions or ulcerations
Endoscopic
findings
Round or oval ulcers,
punched-out lesions
with discrete margins
(>1 cm), focal
distribution (<5 ulcers)
Longitudinal ulcers,
cobblestone appearance,
aphthous ulcers showing
longitudinal array
Mucosal erythema, fine
granularity, loss of
vascular marking,
erosions, ulcers,
spontaneous bleeding,
luminal narrowing with
pseudopolyps
Localization Terminal ileum,ileocecal region, colon
Small bowel,
upper-gastrointestinal
tract
Starts in the rectum and
extends proximally in a
continuous manner
through the entire colon
partakes probably in somehow the disease onset and the
successful use of anti-TNF-𝛼 agents has substantiated the role
of this cytokine in BD [10–12]. Conversely interleukin- (IL-)
6 seems to be related to central nervous system involvement,
as confirmed by its high levels in the cerebral spinal fluid of
affected patients [13]. Recent studies have also suggested a
role of IL-1, since its secretion in BD patients appeared to be
related to NLRP3 inflammasome activation [14–17].
Although oral aphthae and genital ulcers are the earliest
and the most frequent manifestations of BD, anticipating by
many years other typical BD clinical symptoms, GIBD is
one of the major causes of morbidity and mortality, often
leading to severe complications. GIBD occurs in 3–60%
of patients, on average 4.5–6 years after the onset of oral
ulcerations [18], varying among different populations [2, 19–
21] and being more frequent in Japan, United Kingdom, and
Taiwan than in the Middle East and Mediterranean basin
[4, 22, 23]. Intestinal ulcerations are the main pathological
features ofGIBD, and it is thought they are secondary to small
vessel vasculitis, albeit a large vessel involvement leading to
ischemic damage may arise [24]. GIBD may be suspected
when diarrhoea, melena, and hematochezia occur [25–27].
Common complaints may include abdominal pain, fever,
anorexia, vomiting, and dyspepsia, and a palpable mass on
the affected quadrant can also be noticed [25]. The terminal
ileum is themost common localization of disease, followed by
the ileocecal region and colon [28]; esophagus engagement is
unusual [29], and rectum or anus is also rarely affected [30]
while the stomach is the least frequently involved part of the
gastrointestinal tract [31, 32]. Table 1 shows themost common
intestinal localizations of BD.
Gastrointestinal lesions are typically irregular, round or
oval, punched-out, large (>1 cm), single to a few in number,
deep, and with discrete margins in a focal distribution [33].
On the basis of endoscopic findings, they are classified into
volcano, geographic, and aphthous types. The volcano-type,
deeply penetrating and having nodular margins caused by
fibrosis, is strictly associated with a poor prognosis [34, 35].
The differential diagnosis between GIBD and inflammatory
bowel disease, in particular Crohn’s disease (CD), is often
difficult, albeit in the latter the ulcers have typically a
cobblestone appearance with a segmental distribution which
involves irregularly different parts of the gastrointestinal
tract [33]. In this regard a diagnostic algorithm using a
classification analysis of the lesions has been proposed in
order to identify valuable strategies for differential diagnosis
[36]. A clinical scoring system known as the Disease Activity
Index for Intestinal BD (DAIBD) provides a score between
0 and 325 based on an 8-point index; it classifies disease
activity as quiescent (≤19), mild (20–39), moderate (40–74),
and severe (≥75) on the basis of patient’s general condi-
tion, extraintestinal manifestations, intestinal symptoms and
signs, and stool frequency [37]. Table 1 summarizes the main
clinical, endoscopic, and pathological findings of GIBD.
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Although a wide number of conventional immunosup-
pressive drugs have been used to induce remission in GIBD,
several failures have been reported. This article reviews the
progress in the management of GIBD focusing on current
treatment strategies and possible future perspectives. An
electronic literature search was conducted using the PubMed
database and the clinicaltrials.gov search engine. We looked
for all studies published in the last years, including case
reports, clinical trials, and cohort studies (Table 2).
2. The Management of GIBD
As underlined in the guidelines of the European League
Against Rheumatism (EULAR) for the management of BD,
evidence-based recommendations regarding GIBD are not
provided due to the poor amount of published clinical
trials [38]. Medical treatment such as corticosteroids (CC),
sulfasalazine (SSZ), and azathioprine (AZA) are capable of
inducing remission without the need for surgery in many
patients [25, 39], whereas TNF-𝛼 antagonists and thalido-
mide (THD) have proven useful in resistant and complicated
cases [10–12, 40, 41].
Nevertheless GIBD management is still largely empirical
due to the lack of not yet standardized medical treatments,
the heterogeneity of this disorder, and the unpredictable
exacerbations of BD. To date, several conventional immuno-
suppressive drugs may be employed, although none of them
has been proven actually effective in preventing disease
relapse.
2.1. Corticosteroids (CC). CC are the first-line therapy, espe-
cially in patients with severe systemic symptoms, recur-
rent gastrointestinal bleeding, or when treatment with 5-
aminosalicylic acid (5-ASA)/SSZ is not enough [42]. CC are
supposed to be very effective in the short term; indeed it is
widely accepted to start with prednisolone or its equivalent
at 0.5–1mg/kg which has to be quickly tapered by 5 mg
each week within few months [43]. The rationale behind this
strategy may be figured out noticing the evidence reported
by Park et al. in a retrospective cohort study; systemic CC
therapy (mean starting dose, 0.58mg/kg) was administered
in 54 patients with active GIBD; a complete remission and
partial remission were achieved in 46.3% and 42.6% of
patients respectively, whereas only 11.1% showed no response
one month after starting treatment. At one-year follow-up,
a prolonged response was found in 26 out of 54 patients,
whereas 19 patients showed CC dependency, suggesting that
their employment is not desirable over extended periods
[44]. Several literature data report the association between
CC employment and GI side effects, including bleeding or
perforation. GI bleeding and perforation are assumed to
occur when ulcers erode into underlying vessels. CC may
impair tissue repair, thus leading to delayed wound healing.
Despite these assumptions, a recent systematic review and
meta-analysis of randomised, double-blind, controlled trials
comparing CC to placebo for any medical condition or in
healthy participants have suggested that additional factors
to corticosteroid therapy, such as severe physiological stress,
may decrease mucosal blood flow with subsequent tissue
ischemia making some patients more vulnerable to adverse
events under CC assumption. Therefore acid-suppressive
therapy may be considered a valuable aid in preventing the
occurrence of ulcers in clinical settings [45].
2.2. 5-Aminosalicylic Acid (5-ASA)/Sulfasalazine (SSZ). 5-
ASA/SSZ is indicated in all cases of GIBD due to its safety
profile and current limited therapeutic options [46]. It is
usually administered at a dose of 2–4 g/day for inducing
remission in mild forms of BD and for maintenance once
remission is achieved [27]. Convincing evidence about the
efficacy of 5-ASA derives from nonrandomized studies and
case series suggesting that it is effective in treating esophageal
and gastrointestinal manifestations of BD [47, 48], albeit
conflicting data regarding its usefulness have been reported
as well [49]. In a retrospective cohort study investigating
143 patients with GIBD who received 5-ASA/SSZ alone for
maintaining remission, cumulative relapse rates at 1, 3, 5, and
10 years after remission were 8.1%, 22.6%, 31.2%, and 46.7%,
respectively. Of note, a younger age at diagnosis (<35 years),
higher serum level of C-reactive protein (1.5mg/dL), and
greater DAIBD score (≥60) were regarded as independent
predictors of relapse [50]. More recently an observational
study has suggested 5-ASA as a valuable treatment for pre-
venting postoperative recurrences; remission was achieved in
10 out of 16 (62.5%) patients who took 5-ASA compounds,
and no exacerbation was seen during the 89.3 ± 64.5 months
that they were followed. Similarly, remission was observed
also among 37 patients who were prescribed with azathio-
prine, and there were no relapses in 24/37 (65%) patients
during a mean follow-up of 68.6 ± 43.6 months [51].
2.3. Thalidomide (THD). THD is an immunomodulatory
drug, used mainly in the treatment of specific tumors. It is
usually considered the last-line therapy for GIBD, albeit its
use is well-documented [52].The immunomodulatory effects
of THD are due to the reduction in levels of TNF-𝛼 because
of degradation of its encoding mRNA [53]. A pilot study
[54] and three open studies [55–57] have demonstrated THD
effectiveness in the treatment of BD with mucocutaneous
involvement as well as in CD enteric involvement [58].
Yasui et al. reported the benefits of THD in 7
juvenile−onset patients with severe, recurrent GIBD
who had previously failed immunosuppressant treatments
and developed significant CC toxicity. THD was given at the
initial dose of 2mg/kg per day and was increased to 3mg/kg
per day if necessary. All patients showed dramatic improve-
ment in clinical symptoms, and CC were successfully with-
drawn [59]. Yet, the efficacy of THD has been also reported
on four BD patients with relapsing gastrointestinal disease
who required the frequent use of systemic CC. Three out
of the four patients had a clinical improvement on THD
treatment and all discontinued CC therapy suggesting
that THD could be considered a therapeutic option for
treatment of refractory GIBD [60]. More recently Hatemi
et al. described their experience on 13 patients with GIBD
refractory to the conventional therapy who were treated with
TNF-𝛼 antagonists and/or THD; a clinical and endoscopic
remission was obtained in 10 out of 13 patients (about 75% of
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Table 2: Overview of studies derived from themedical literature reporting treatment indications of gastrointestinal lesions in Behc¸et’s disease.
Drugs Dose Authors (year) Number ofpatients Type of study Outcomes
5-ASA/SSZ 2.4–4 g/day Jung et al.(2012) 143/292
Retrospective
cohort study
Positive effect in
maintaining remission
THD
2-3mg/kg/day
Yasui et al.
(2008) 7 Case series Dramatic improvement inclinical symptoms
— Lee et al.(2010) 4 Case series
3/4 patients had a clinical
improvement and all
discontinued steroid
therapy
THD/IFX/ADA/
ETA
THD 50–100mg/day
IFX 5mg/kg every 8
weeks
ADA 160mg at week
0 and 80mg at week
2, followed by 40mg
every other week
ETA 25mg twice a
week
Hatemi et al. (2015) 13/64 Observationalstudy
Remission obtained with
TNF-𝛼 antagonists and/or
THD in about 75% of cases.
AZA or 6-MP
AZA 2–2.5mg/kg/day
6-MP
0.5–1.5mg/kg/day
Jung et al.
(2012) 67/272
Retrospective
study
Relative good effect for
maintenance of remission
AZA or 6-MP
vs
5-ASA
AZA 2–2.5mg/kg/day
or
6-MP 1–1.5mg/kg/day
vs
5-ASA 3-4 g/day
Lee et al.
(2015) 77
Retrospective
observational
study
The rates of reoperation,
readmission, and death
were not significantly
different between the
5-ASA and thiopurine
groups
MTX + IFX
MTX -
FX 3–5mg/kg every 8
weeks
Iwata et al.
(2011) 10
Observational
study
Long-term alleviation of
entero-BD and excellent
tolerability with
combination of IFX and
MTX
INF-𝛼
6 × 106 IU per day for
14 days
Grimbacher et al.
(1997) 1 Case report
Complete remission of
Behc¸et’s retinal infiltrates
and BD-related colitis
3 × 106 IU/day 3
times/week increased
to 6 × 106 IU/day 3
times/week
Monastirli et al.
(2010) 1 Case report
Complete remission of all
clinical manifestations
IVIg 400mg/kg/day for 5days per month
Cantarini et al.
(2016) 1/4 Case series
Complete disease remission
of gastrointestinal,
manifestations
IFX
— Ideguchi et al.(2014) 7/43
Retrospective
observational
study
Good response in two
patients, remission in one,
partial response in two, and
unchanged GI lesions in
two patients
5mg/kg/every 8
weeks
Lee et al.
(2013) 28
Multicenter
retrospective study
IFX efficacy for patients
with moderate-to-severe
intestinal BD
5mg/kg every 8 weeks Kinoshita et al.(2013) 15/43
Retrospective
cohort study
Acceptable efficacy of IFX
in BD patients refractory to
conventional treatments
5mg/kg every 8 weeks Hibi et al.(2016) 11/18 Open-label study
IFX efficacy in the
treatment of intestinal BD
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Table 2: Continued.
Drugs Dose Authors (year) Number ofpatients Type of study Outcomes
ADA
160mg at week 0 and
80mg at week 2,
followed by 40mg
every other week
Tanida et al.
(2015) 20
Multicenter,
open-label,
uncontrolled study
ADA effectiveness in
inducing and maintaining
clinical improvement and
remission in patients with
intestinal BD
160mg at week 0 and
80mg at week 2,
followed by 40mg
every other week
Tanida et al.
(2016) 8
Retrospective
observational
study
Long-term efficacy and
safety of ADA for the
treatment of intestinal BD
in the clinical setting
ETA 25mg twice a week Ma et al.(2014) 19/35
Observational
study
The relapse rate for
etanercept therapy was
reduced significantly when
compared with
conventional therapy
ANA
100mg/day
2mg/kg/day
increased to
2.5mg/kg/day
Cantarini et al.
(2013) 3/9 Case series
Complete resolution of
abdominal pain in two
patients,
relapse in one patient
CANA
150mg every 8 weeks
150mg every six
weeks
Vitale et al.
(2013) 2/3 Case series
Complete resolution of
abdominal pain
TCZ 8mg/kg/ every 4weeks
Deroux et al.
(2015) 3/4 Case series
Less effective for arthralgia
and abdominal pain
ADA, adalimumab; ANA, anakinra; anti-TNF-𝛼, anti-tumor necrosis factor-𝛼; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine; CANA, canakinumab; ETA,
etanercept; INF-𝛼, interferon 𝛼; IFX, infliximab; IVIg, intravenous immunoglobulins; 6-MP, 6-mercaptopurine; MTX, methotrexate; SSZ, sulfasalazine; TCZ,
tocilizumab; THD,Thalidomide.
the cases) proving the favourable response with anti-TNF-𝛼
agents and/or THD in GIBD [61].
Despite the efficacy and safety profile reported in several
bodies of evidence of the literature [59, 62, 63], more data
from clinical trials are necessary to define the proper use of
this widely known teratogenic drug.
2.4. Other Immunomodulators. Thiopurines including 6-
mercaptopurine (6-MP) and its prodrug AZA have been
traditionally thought to decrease reoperation rate in patients
with GIBD who already had undergone surgical interven-
tions [25]. The initial dose of AZA is 25–50mg/day with
gradual increase every 2–4 week to 2.0–2.5mg/kg [64]. Simi-
larly the starting dose of 6-MP is 0.5mg/kg escalated every
2–4 weeks to an optimal dosing regimen of 1.0–1.5mg/kg.
Data on the questionable effectiveness of thiopurine treat-
ment in patients with GIBD derive from a retrospective
analysis aimed at investigating predictors of clinical relapse
in 67 patients with GIBD receiving thiopurine maintenance
therapy; a cumulative relapse rates of 5.8%, 28.7%, 43.7%,
and 51.7% at 1, 2, 3, and 5 years, respectively, after remission
were recorded. Although thiopurine therapy has proven to be
relatively effective for maintenance of remission in GIBD, a
younger age at diagnosis (<25 years) and a lower hemoglobin
level (<11 g/dL) were associated with a poor response to this
treatment [65].
Yet, a recent retrospective observational studywas carried
out to assess the efficacy of postoperative thiopurine therapy
in 77 patients with GIBD; although a lower postoperative
recurrence was found in patients who received thiopurines
than those taking 5-ASA, the rates of reoperation, readmis-
sion, and death were not significantly different between the
5-ASA and thiopurine groups [66].
Evidence concerning the efficacy of methotrexate com-
bined with infliximab (IFX) in refractory entero-BD has
been also reported in 9 out of 10 patients who experienced
the disappearance of ileocecal ulcerations at 12 months of
therapy [67]. In addition, anecdotal case reports describing
the effectiveness of tacrolimus [68] and chlorambucil [69] for
treating intestinal lesions in BD have been also described.
Interferon (IFN) is a cytokine able to render cells resistant
to infection by many viruses. It was introduced for the
treatment of BD by Tsambaos in 1986, because of its antiviral
and antiproliferative properties [70]. The most impressive
results have been achieved for severe and/or refractory ocular
manifestations; however IFN-𝛼 could represent a promising
treatment option for neurologic and gastrointestinal involve-
ment in BD [71]. In this regard Grimbacher et al. reported a
complete remission of BD retinal infiltrates and BD-related
colitis after treatment with IFN-𝛼 [72], and similar proofs
supporting the benefits of IFN-𝛼 also derive from the study
by Monastirli et al. [73].
During the last few decades intravenous immunoglobu-
lins (IVIg) have been increasingly administered for a wide
number of autoimmune and systemic inflammatory diseases.
To the best of our knowledge, IVIg have so far been evaluated
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in few patients with GIBD. In this regard, the efficacy of
IVIg has been reported in a patient with BD-related colitis
who initially had failed under CC and immunosuppressive
therapy [19], as well as in a patient with GIBD complicated by
the presence of immune deficiency [74]. More recently, four
BD patients, one of whom suffered from neurological and
gastrointestinal involvement, refractory to standard treat-
ments and responsive to IVIg therapy have also been
described [75].
2.5. Biological Drugs. Several data suggest a role of TNF-
𝛼 in the pathogenesis of BD; a remarkable upregulation of
TNF-𝛼 and soluble TNF receptors [76] as well as a great
amount of 𝛾𝛿+ T cells producing TNF were found in the
peripheral blood of patients with active disease [77]. Cur-
rently, the monoclonal antibodies anti-TNF-𝛼 IFX [78] and
adalimumab (ADA) [79] alongwith the humanTNF receptor
p75 Fc fusion protein etanercept (ETN) [80] have been
advocated for the treatment of different BD manifestations.
The administration schedule of IFX for treating GIBD is
adopted from the regimen employed in the management of
CD (5mg/kg intravenous at weeks 0, 2, and 6) [81]. A clinical
remission of intestinal BD lesions and the rapid healing
of ulcers after treatment with IFX have been described in
several case reports (10, 40, 82–90). The short and long-
term effects of IFX on the clinical course and intestinal
manifestations of BD were assessed by abdominal computed
tomography and colonoscopy in ten patients with entero-BD
refractory to the conventional therapies; all patients showed
improvement of gastrointestinal symptoms and disease-
associated complications within 4 weeks. Furthermore, the
rate of disappearance of ileocecal ulcerations was 50%
(5/10 patients) at 6 months and 90% (9/10 patients) at 12
months [67]. On the contrary, the results derived from a
retrospective observational study enrolling 43 patients with
GIBD were not entirely encouraging; in this context, IFX
chosen as optional treatment in 7 patients refractory to
conventional therapies led to clinical remission only in one
case (14%) [82].
Yet, a Korean multicenter retrospective study aimed at
investigating the response to IFX in 28 patients with GIBD
showed a clinical response rate of 64.3% with a clinical
remission rate of 28.6% at week 4, following IFX infusion.
Furthermore, an older age at diagnosis (≥40 years), the
female sex, a longer disease duration (≥5 years) as well as
the concomitant immunomodulator use, and achievement of
remission at week 4 were regarded as predictive factors of
sustained response [83].
The efficacy of IFX in GIBD has also been corrobo-
rated by a retrospective cohort study on 15 patients with
active disease refractory to conventional medications. 80% of
patients exhibited a good response to IFX and 53% of them
achieved remission after 10 weeks. Moreover 64% and 50% of
patients maintained the response to IFX at 12 and 24 months,
respectively [84]. More recently an open-label single-arm
phase 3 study carried out on 18 BD patients including 11
with GIBD suggested that IFX was able to induce a clinical
amelioration along with decrease in C-reactive protein levels
after week 2. Consistently, the healing of the main intestinal
ulcers was found in more than 80% of these patients after
week 14. Interestingly, 3 patients who had loss of response to
IFX showed complete resolution of symptoms by increasing
its dosage to 10mg/kg [85].
Finally, an interventional open-label single-arm study
testing the efficacy of IFX by assessing the mean decrease
in DAIBD score in patients with active intestinal disease
refractory to conventional therapies is currently recruiting
participants (ClinicalTrials.gov, NCT02505568).
To date, few data are available regarding ADA efficacy in
GIBD, although the proofs of its usefulness are increasing
[86–88]. In this regard, ADA has been already successfully
used in three patients with BD-related colitis/esophageal
ulcers [89] and for the first time in the context of a familial
case of GIBD [90].
However, the most consistent evidence regarding ADA
efficacy derives from a phase 3, multicenter, open-label
uncontrolled study evaluating Japanese patients with active
intestinal BD nonresponsive to standard therapies. Twenty
patients received induction treatment with ADA (160mg at
week 0, baseline, and 80mg at week 2, followed by 40mg
every otherweek for 52weeks); a composite index, combining
GI symptoms and endoscopic assessments, was used to
evaluate the efficacy of treatment. A marked improvement,
defined as values ≤1 for both the global GI symptoms and
endoscopic assessment scores, was seen in 60% of patients at
week 52. Interestingly 20% of patients achieved a complete
remission, defined as global GI symptoms and endoscopic
scores of 0, at weeks 24 and 52, suggesting that ADA
was an effective therapy to induce and maintain clinical
improvement and remission in patients withGIBD [91].More
recently, a retrospective study on 8 BDpatients with intestinal
BD, confirmed the long-term (52 weeks) efficacy and safety of
ADA for the treatment ofGIBD [92].Of note, two prospective
observational studies (clinicaltrials.gov NCT02687828 and
NCT01960790) testing the safety and efficacy of ADA for the
treatment of GIBD are now ongoing.
Less experience has been gained focusing on the man-
agement of GIBD with ETA treatment [93]. Recently Ma et
al. have proven the superiority of ETA in GIBD as com-
pared to conventional therapy, assessing the disappearance of
intestinal ulcers confirmed by endoscopy. The healing rate of
intestinal ulcers in the group treated with ETA (19 patients)
was 89.47%, whereas in the group undergoing conventional
treatments (35 patients) it was 51.42%.Therefore, these results
proved a better curative effect of ETA as compared to conven-
tional therapies [94].
Although the employment of anti-IL-1 agents on vari-
ous BD manifestations has been well-documented [95–97],
limited data are available for their efficacy in GIBD, being
represented only by single-case reports and small case series
that describe a clinical amelioration of symptoms without a
clear improvement of organic lesions [15–17]. Similarly, albeit
IL-6 could be a relevant therapeutic target for refractory BD
and its activity can be blocked using the anti-IL-6 receptor
antibody tocilizumab [98, 99], inconsistent are the literature
data concerning the efficacy of this biologic drug inmanaging
BD clinical manifestations that differ from the neurological
ones [100–102].
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2.6. Stem Cell Transplantation. Haematopoietic stem cell
transplantation (HSCT) has been used in the treatment of
severe autoimmune and inflammatory conditions unrespon-
sive to conventional therapy. Although several treatment
options, including biologic agents, are till now available for
BD management, there is still an unmet need for more
effective therapies for patients who are refractory to conven-
tional treatments. In this regard encouraging results derive
from several case reports describing HSCT in GIBD patients
transplanted for accompanying haematological conditions.
A complete remission of GI findings was observed after
HSCT and there was no need to treat patients with any
medications [103, 104]. This evidence suggests that HSCT
may be an effective alternative in BD patients with severe
organ involvement, especially GI involvement refractory to
immunosuppressives. However, one must make sure that
the benefit outweighs the risks when developing a manage-
ment strategy for these patients. Since HSCT can be a life-
threatening procedure, mostly autologous transplants should
be preferred to those allogenic which may lead to major
complications such as infections, GVHD, and hepatic, renal,
and pulmonary damage [105].
2.7. Surgery. Surgery is indicated when patients with GIBD
are refractory to medical treatment or serious complications,
such as when gastrointestinal bleeding, perforation, fistulae,
obstructions, and abdominal masses occur [106]. Bowel
perforation is one of the most feared complications of GIBD.
In this regard a retrospective study analysing free bowel wall
perforation in 129 subjects with GIBD showed that 25.6% of
patients experienced surgery for bowel perforation. Of them,
42.4% showed postoperative recurrence and 33.3% under-
went reoperation. In addition, a younger age at diagnosis (≤25
years), an experience of prior laparotomy, and the presence
of volcano-shaped ulcers were regarded as independent risk
factors for free bowel perforation [107]. Resection involving
sufficient margin and including normal bowel has been
widely accepted in surgery [108, 109]. However, some bodies
of evidence have proven that resection length is not related to
postoperative recurrence in patients with GIBD, prospecting
a less invasive surgical approach [39, 106]. Intestinal leakage,
perforation, and fistula formation seems to occur more
frequently at the anastomotic site; consequently, the creation
of a stoma is preferred over primary anastomosis [18].
3. Conclusions
BD is a complex syndrome characterized by significant
heterogeneity of clinical manifestations with usually frequent
relapses. GIBD is one of the most severe manifestations
of this disease, causing serious complications such as per-
foration and gastrointestinal bleeding. GIBD shares many
clinical features with inflammatory bowel diseases, and for
this reason it represents a pitfall for physicians regarding
differential diagnosis at the first presentation. Nevertheless,
a careful evaluation of endoscopic findings may help in the
diagnostic interpretation, whereas the endoscopic biopsy is
necessary to confirm a histopathologic diagnosis. Treatments
have been largely unsatisfactory, creating significant unmet
needs, and the lack of evidence-based treatment makes the
management of GIBD very challenging. Currently, several
immunosuppressive drugs such as SSZ, CC, and AZA are
generally well-tolerated but often associated with increased
risk of disease relapses as a result of which surgery is
required inmany patients. In the last years, new pathogenetic
hypotheses supported the use of biotechnological drugs,
mostly TNF-𝛼 inhibitors, which represent new tools in
the therapeutic armamentarium for managing patients with
GIBD, particularly those who are resistant to conventional
immunosuppressant drugs. On this basis the main goal of
treatment should be aimed at avoiding and preventing the
feared complications of GIBD that endanger the life of these
patients.
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